Alfonso Del Cuvillo Bernal-rekin lankidetzan egindako argitalpenak (8)

2013

  1. ESPRINT-15 questionnaire (Spanish version): Reference values according to disease severity using both the original and the modified ARIA classifications

    Journal of Investigational Allergology and Clinical Immunology, Vol. 23, Núm. 1, pp. 14-19

2012

  1. The impact of allergic rhinitis on symptoms, and quality of life using the new criterion of ARIA severity classification

    Rhinology, Vol. 50, Núm. 1, pp. 33-36

2010

  1. Discrimination between moderate and severe disease may be used in patients with either treated or untreated allergic rhinitis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 65, Núm. 12, pp. 1609-1613

2009

  1. Reference values for facilitating the interpretation of the ESPRINT-15 Questionnaire (Spanish Version)

    Journal of Investigational Allergology and Clinical Immunology, Vol. 19, Núm. 5, pp. 396-403

  2. Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: A multicentre, open-label study in Spain

    Drug Safety, Vol. 32, Núm. 1, pp. 33-42

2007

  1. A new criterion by which to discriminate between patients with moderate allergic rhinitis and patients with severe allergic rhinitis based on the Allergic Rhinitis and its Impact on Asthma severity items

    Journal of Allergy and Clinical Immunology, Vol. 120, Núm. 2, pp. 359-365

  2. Development and validation of a new Spanish instrument to measure health-related quality of life in patients with allergic rhinitis: The ESPRINT questionnaire

    Value in Health, Vol. 10, Núm. 6, pp. 466-477

  3. Health-related quality of life in allergic rhinitis: Comparing the short form ESPRINT-15 and MiniRQLQ questionnaires

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 62, Núm. 12, pp. 1372-1378